Ticker Details
Beam Therapeutics Inc.
IPO Date:	February 6, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.69B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.56 | 3.71%
Avg Daily Range (30 D):	$1.15 | 3.53%
Avg Daily Range (90 D):	$0.98 | 3.36%

Institutional Daily Volume
Avg Daily Volume:	1.06M
Avg Daily Volume (30 D):	1.98M
Avg Daily Volume (90 D):	1.86M

Trade Size
Avg Trade Size (Sh.):	59
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	54

Institutional Trades
Total Institutional Trades:	3,681
Avg Institutional Trade:	$3.2M
Avg Institutional Trade (30 D):	$3.84M
Avg Institutional Trade (90 D):	$3.66M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.11M
Avg Closing Trade (30 D):	$11.1M
Avg Closing Trade (90 D):	$8.12M
Avg Closing Volume:	150.69K

News

Jul 3, 2026 @ 8:44 AM Gene Editing Therapeutics: Transforming Biopharmac... Source: Researchandmarkets.Com

Jul 3, 2026 @ 8:41 AM Global CRISPR-Based Drug Development Platforms Mar... Source: Researchandmarkets.Com

May 26, 2026 @ 12:35 AM Better Gene-Editing Stock: CRISPR Therapeutics or ... Source: Prosper Junior Bakiny

May 18, 2026 @ 8:00 PM Beam Therapeutics Presents Recently Reported Topli... Source: Beam Therapeutics Inc.

Apr 27, 2026 @ 4:09 PM S&P 500 Holds Near Highs Despite Oil Shock and Wea... Source: Itai Smidt

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.5	$-.91	$2.51
Diluted EPS	$-.5	$-.91	$2.51
Revenue	$164.01M	$31.74M	$114.11M
Gross Profit
Net Income / Loss	$-65.04M	$-94.32M	$244.3M
Operating Income / Loss	$-371.62M	$-107.22M	$-17.45M
Cost of Revenue
Net Cash Flow	$-239.53M	$-6.64M	$27M
PE Ratio